Cyclerion-Korsana Merger Sparks 160% Stock Surge in Alzheimer's Drug Race

Cyclerion Therapeutics has agreed to merge with Korsana Biosciences in a deal that sent its shares soaring by over 160% in pre-market trading. The combined company will operate under the name Korsana Biosciences and trade on Nasdaq as 'KRSA'. Existing Cyclerion shareholders will retain just 1.5% of the new entity, while Korsana investors will hold the remaining 98.5%.

The merger centres on Korsana's lead drug, KRSA-028, a novel Alzheimer's treatment designed for subcutaneous delivery. Unlike current intravenous therapies, this approach aims to improve convenience for patients while targeting amyloid beta with Korsana's proprietary technology.

Korsana's flagship candidate, KRSA-028, uses the company's Therapeutic Targeting platform to bind amyloid beta in Alzheimer's patients. Phase 1 trial results are expected by mid-2027, with proof-of-concept data due by the end of that year. The drug is formulated for under-the-skin injection, offering a potential advantage over existing IV treatments.

Korsana has already secured $380 million in private funding from backers including Fairmount, Venrock Healthcare Capital Partners, and Sanofi Ventures. The company's pipeline also targets tau protein aggregates, a hallmark of Alzheimer's progression. Preclinical studies suggest its tau-binding approach could achieve 40% greater cognitive stabilisation compared to standard therapies, with fewer side effects. Following the merger, Jonathan Violin will continue as CEO of the combined business. Korsana's current board, including chairman Tomas Kiselak from Fairmount, will transition to the new company. Wedbush Securities advised Korsana on the deal, while Gemini Valuation Services supported Cyclerion. Cyclerion had been reviewing strategic options before the merger and will now scale back earlier projects, including CYC-126 and its partnership with Medsteer. The focus will shift entirely to Korsana's Alzheimer's programmes, with milestones including a Phase 1 completion in 2026, Phase 2 results by late 2027, and a planned commercial launch in 2030.

The merger positions Korsana Biosciences as a key player in Alzheimer's research, with a pipeline targeting both amyloid beta and tau proteins. KRSA-028's subcutaneous delivery could simplify treatment compared to current IV options. The company now moves forward under Nasdaq's 'KRSA' ticker, with leadership and funding already in place to advance its clinical programmes.